Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Interest & Investment Income (2021 - 2026)

Viridian Therapeutics, Inc.\DE has reported Interest & Investment Income over the past 5 years, most recently at $7.8 million for Q4 2025.

  • Quarterly results put Interest & Investment Income at $7.8 million for Q4 2025, down 8.54% from a year ago — trailing twelve months through Dec 2025 was $27.4 million (down 13.75% YoY), and the annual figure for FY2025 was $27.4 million, down 13.29%.
  • Interest & Investment Income for Q4 2025 was $7.8 million at Viridian Therapeutics, Inc.\DE, up from $5.5 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for VRDN hit a ceiling of $8.5 million in Q4 2024 and a floor of $34000.0 in Q2 2021.
  • Median Interest & Investment Income over the past 5 years was $4.5 million (2023), compared with a mean of $4.3 million.
  • Biggest five-year swings in Interest & Investment Income: skyrocketed 2399.28% in 2022 and later fell 26.53% in 2025.
  • Viridian Therapeutics, Inc.\DE's Interest & Investment Income stood at $138000.0 in 2021, then skyrocketed by 2399.28% to $3.4 million in 2022, then soared by 51.09% to $5.2 million in 2023, then skyrocketed by 63.5% to $8.5 million in 2024, then fell by 8.54% to $7.8 million in 2025.
  • The last three reported values for Interest & Investment Income were $7.8 million (Q4 2025), $5.5 million (Q3 2025), and $6.5 million (Q2 2025) per Business Quant data.